Five Prime Therapeutics, Inc. (NASDAQ:FPRX) Files An 8-K Regulation FD Disclosure
Item7.01
| Regulation FD Disclosure. |
On May17, 2017, abstracts for two clinical poster presentations
that Five Prime Therapeutics, Inc. (FivePrime) will present at
the 2017 American Society of Clinical Oncology (ASCO) Annual
Meeting were published to ASCOs website. The abstracts review
updated clinical data on FivePrimes ongoing Phase 1 clinical
trial of FPA144 in gastric cancer and FivePrimes Phase 1/2
clinical trial of cabiralizumab in pigmented villonodular
synovitis. The full titles of the abstracts are: Updated
antitumor activity and safety of FPA144, an ADCC-enhanced, FGFR2b
isoform-specific monoclonal antibody, in patients with FGFR2b
gastric cancer and A phase 1/2 dose escalation and expansion
study of cabiralizumab (cabira; FPA008), an anti-CSF1R antibody,
in tenosynovial giant cell tumor (TGCT, diffuse pigmented
villonodular synovitis D-PVNS). Copies of the abstracts are
furnished as Exhibit 99.1 and Exhibit 99.2, respectively, to this
Current Report on Form 8-K and are incorporated herein by
reference.
The information provided in this Form 8-K, including Exhibits
99.1 and 99.2 hereto, shall not be deemed filed for purposes of
Section18 of the Securities Exchange Act of 1934, as amended (the
Exchange Act), or otherwise subject to the liabilities of that
section, nor shall it be deemed incorporated by reference in any
filing under the Securities Act of 1933, as amended, or the
Exchange Act, except as expressly set forth by specific reference
in such filing.
| Item9.01 | Financial Statements and Exhibits. |
(d) Exhibits.
|
Exhibit No. |
Description |
|
| 99.1 |
Abstract titled Updated antitumor activity and safety of FPA144, an ADCC-enhanced, FGFR2b isoform-specific monoclonal antibody, in patients with FGFR2b gastric cancer |
|
| 99.2 |
Abstract titled A phase 1/2 dose escalation and expansion study of cabiralizumab (cabira; FPA008), an anti-CSF1R antibody, in tenosynovial giant cell tumor (TGCT, diffuse pigmented villonodular synovitis D-PVNS) |
2
About Five Prime Therapeutics, Inc. (NASDAQ:FPRX)
Five Prime Therapeutics, Inc. (Five Prime) is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company has three product candidates in clinical development covering multiple potential indications. It focuses on immuno-oncology, an area in which it has clinical and discovery programs, and product and discovery collaborations. The Company seeks to engage third-party collaborators to assist it in developing companion diagnostics for its clinical programs. The Company’s product candidates include FPA008, FPA144 and FP-1039/GSK3052230. The FPA008 is an antibody that inhibits colony stimulating factor-1 (CSF1), receptor (CSF1R). The FPA144 is an antibody that inhibits fibroblast growth factor receptor 2b (FGFR2b). FP-1039 is a protein therapeutic designed to trap and neutralize cancer-promoting fibroblast growth factors (FGFs). Five Prime Therapeutics, Inc. (NASDAQ:FPRX) Recent Trading Information
Five Prime Therapeutics, Inc. (NASDAQ:FPRX) closed its last trading session down -1.51 at 29.26 with 278,652 shares trading hands.
